<DOC>
	<DOCNO>NCT01518205</DOCNO>
	<brief_summary>Diabetic foot ( DF ) common , severe costly complication diabetes . DF underlie neuropathy , atherosclerosis distal artery infection , result tissue ulcer necrosis . Alterations microcirculatory function blood rheology may concur cause tissue damage . In recent year accumulate evidence LDL apheresis ( LA ) reduce cholesterol also series pleiotropic effect improve microcirculation , increase peripheral tissue perfusion . HADIF randomize , multicentric , prospective clinical study aim assess effect LDL apheresis treatment association traditional therapy ulcer , patient ischemic diabetic foot ulcer ( class I II Texas Wound Classification System ) peripheral vasculopathy susceptible revascularization . A total 132 patient enrol . Participants centrally randomize receive traditional therapy alone ( TT ) association LA . TT include standard medication ulcer , antiaggregant therapy statin . LA perform HELP system , total 10 session 9 week . The primary end-point study ulcer healing ; secondary endpoint include improvement peripheral oxygenation , resolution pain , reduction circulate inflammatory marker , cardiovascular event one year 's follow-up . This clinical Study approve local EC 25 may 2011 ( Study number 1953 ) . TO BE NOTED : since diabetic patient `` Diabetic-Foot UNIT '' often presented foot ulcer severe class II Texas , formal amendment submit EC recruit patient diabetic foot ulcer class III Texas . The amendment already approve 5 may 2012 .</brief_summary>
	<brief_title>HELP-Apheresis Diabetic Ischemic Foot Treatment ( H.A.D.I.F )</brief_title>
	<detailed_description>Aim protocol evaluate effect LDL-apheresis combination traditional therapy , recovery diabetic ulcer patient suffer diabetic ischemic foot peripheral vasculopathy revascularized . Patients qualify study randomized traditional treatment combine apheresis ( Experimental Arm ) standard treatment ( control Arm ) . The randomization stratify accord lesion gravity level ( class TEXAS I vs II v III ) , allocation 1:1 . The randomization list generate statistic software `` Stata 11 '' . The list randomization ( one list class TEXAS ) generate stored coordinator centre . When patient satisfies study inclusion criterion , contact coordinator centre ( phone/mail ) group allocation . 132 patient enrol ( 66 patient experimental arm , 66 patient control arm ) . Traditional Therapy ( TT ) include standard medication ulcer , antiaggregant therapy statin . LDL-apheresis ( intervention Arm ) perform HELP system , 10 session 9 week . Blood sample collect ( basal , 3-6-9-12 month ) order determine follow parameter : glycaemia , insulin , glycated haemoglobin , microalbuminuria/creatinuria , CBC , fibrinogen , total cholesterol , HDL-cholesterol , LDL-cholesterol , Triglycerides , Lp ( ) , C-reactive protein ( CRP ) , pentraxin3 ( PTX3 ) . Furthermore , patient experimental arm , blood sample collect basal end LDL-apheresis session . 2 10 order determine CBC , fibrinogen , total cholesterol , HDL-cholesterol , LDL-cholesterol , Triglycerides , Lp ( ) , CRP , PTX3 ( time schedule , 1 9 week ) . The value lab test obtain end apheresis normalize due possible hemodilution , accord follow formula : F dil= ( 1 - Htc pre-apheresis ) / ( 1 - Htc post-apheresis ) . Xcorrect = Xmeasured * Fdil . Ulcer evaluation : staging accord Texas Wound classification System ulcer surface evaluation ( diameter , map lesion mean draw profile Opsite film ; digital picture ) : basal , 9th week 3-6-9-12 month follow-up . The ulcer evolution `` blind '' monitor evaluator check ulcer-map digital picture without know randomization arm belong . Transcutaneous oximetry : basal , 4th week ( i.e . 5th apheretic session ) . 9th week ( end 10 apheresis session ) next 3-6-9-12 month follow-up . Questionnaire quality life ( SF36 ) : basal , 9th week ( end 10 apheresis session ) next 6-12 month follow-up . Pain intensity rate ( verbal numeric range ) basal , 9th week ( end 10 apheresis session ) next 3-6-9-12 month follow-up . Doppler flowmeter : basal , 9th week ( end 10 apheresis session ) subsequent follow-up 6 12 month .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Arteriosclerosis Obliterans</mesh_term>
	<criteria>Diabetic patient Ischemic diabetic ulcer ( class I , II III Texas Wound Classification System ) ; document peripheral vasculopathy least previous event fail revascularization ( ulcer healing ) . Patient refusal participate BMI &gt; 35 kg/m2 Ischemic diabetic ulcer class III Texas Wound Classification System Patients present bleed diathesis , malignant tumor , heart failure allow extracorporeal technique . Haemodialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>diabetic foot ulcer ,</keyword>
	<keyword>peripheral arterial disease ,</keyword>
	<keyword>heparin-induced extracorporal lipid apheresis .</keyword>
	<keyword>inflammatory marker</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>LDL-cholesterol</keyword>
</DOC>